ABEMACICLIB is a pill that blocks proteins called CDK4 and CDK6, which help cancer cells grow. By stopping these proteins, the drug slows the growth of certain breast cancers.

PAZOPANIB is an oral medicine that blocks signals that tell tumors to make new blood vessels. Without these vessels, the tumor has less blood supply and grows more slowly.

CAPECITABINE is a chemotherapy taken by mouth that is changed inside the body into a drug similar to 5‑fluorouracil. It interferes with the DNA of cancer cells, stopping them from dividing.

AXITINIB is a tablet that blocks a protein called VEGF receptor, which cancers use to grow new blood vessels. It is used mainly for kidney cancer.

OLAPARIB is a pill that stops cancer cells from repairing their DNA. It works best in cancers that have certain gene changes, such as some breast, ovarian, and prostate cancers.

TIPIRACIL is an oral drug that disrupts the building blocks of DNA in cancer cells, helping to stop their growth, especially in colorectal cancer.

TRIFLURIDINE works together with tipiracil; it gets incorporated into the DNA of cancer cells and prevents them from copying their genetic material, also used for colorectal cancer.

OSIMERTINIB is a tablet that targets a specific mutation in the EGFR gene, which is found in some lung cancers, helping to stop tumor growth.

ENZALUTAMIDE blocks the effect of male hormones on prostate cancer cells, slowing the growth of this type of cancer.

PALBOCICLIB is another CDK4/6 inhibitor taken by mouth that helps control the growth of certain breast cancers by stopping cell division.

RIBOCICLIB also blocks CDK4 and CDK6 proteins, working similarly to other drugs in this class to treat breast cancer.

LENVATINIB is a pill that blocks several proteins that help tumors grow and make new blood vessels. It is used for cancers such as thyroid, kidney, and liver cancer.

BRIGATINIB targets a gene change called ALK that can drive lung cancer, helping to keep the cancer from growing.

EVEROLIMUS is an oral medication that inhibits a pathway called mTOR, which cancer cells use to grow and survive. It is used in a variety of cancers.

CABOZANTINIB blocks multiple signaling proteins that tumors need to grow and spread, and it is used for kidney and liver cancers.

SUNITINIB is a tablet that stops several receptors involved in blood‑vessel formation, slowing the growth of kidney cancer.

ALECTINIB HYDROCHLORIDE is an ALK inhibitor taken by mouth that treats lung cancers with ALK gene changes.

ABIRATERONE ACETATE reduces the body’s production of male hormones that can feed prostate cancer, helping to control the disease.

REGORAFENIB blocks many kinases that tumors use to grow and spread, and it is used for colorectal cancer and other solid tumors.

Hormone receptor‑positive, HER2‑negative advanced breast cancer – a type of breast cancer that grows in response to estrogen or progesterone and does not overexpress HER2. It spreads beyond the breast and may involve lymph nodes or distant sites. The tumor cells continue to divide, leading to gradual increase in size or new lesions. Disease can progress despite hormone therapy.
ALK‑positive non‑small cell lung cancer – a subset of lung cancer where tumor cells contain an abnormal ALK gene that drives growth. It usually presents as a tumor in the lung that can spread to nearby lymph nodes and distant organs. The cancer cells divide rapidly, leading to enlargement of the primary lesion and appearance of metastases. Over time, the disease may become more widespread.
EGFR‑mutated non‑small cell lung cancer – lung cancer driven by mutations in the EGFR gene. The tumor often starts in the airway lining and can extend into surrounding lung tissue and spread. Cancer cells proliferate, causing the tumor to grow and potentially form new sites in other organs. Disease progression is marked by increasing tumor burden.
Metastatic castration‑resistant prostate cancer – prostate cancer that continues to grow despite lowering testosterone levels and has spread beyond the prostate. Cancer cells invade nearby tissues and distant sites such as bone. The disease advances as new lesions appear and existing ones enlarge. It is characterized by ongoing growth without hormonal control.
Metastatic colorectal cancer – cancer that began in the colon or rectum and has spread to other parts of the body, often liver or lungs. Tumor cells detach, travel through blood or lymph, and form new tumors. The disease progresses as these secondary tumors increase in size and number. It reflects continuous spread of malignant cells.
Advanced renal cell carcinoma – kidney cancer that has grown beyond the kidney and may involve blood vessels, lymph nodes, or distant organs. Tumor cells form new blood vessels to support growth, allowing the tumor to enlarge and spread. Disease progression is seen as larger kidney masses and new metastatic sites. It is a slow‑growing but invasive cancer.
Advanced gastrointestinal stromal tumor – a rare tumor arising from the connective tissue of the digestive tract that has spread beyond its original location. Cells proliferate and can invade surrounding organs and travel to the liver or peritoneum. The disease advances as tumors become larger and more numerous. It is characterized by ongoing growth of the stromal cells.
Advanced soft‑tissue sarcoma – a group of cancers that develop in muscles, fat, nerves, or blood vessels and have extended beyond the original site. Tumor cells infiltrate nearby tissues and can disseminate to lungs or other organs. Progression is marked by growth of the primary mass and appearance of distant metastases. The disease continues to expand despite local control.